Published in Hepatology on January 01, 2010
Protein analysis by shotgun/bottom-up proteomics. Chem Rev (2013) 2.13
Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol (2011) 1.85
Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther (2012) 1.55
Adenovirus-36 seropositivity enhances effects of nutritional intervention on obesity, bright liver, and insulin resistance. Dig Dis Sci (2011) 1.16
Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry. Mol Cell Proteomics (2014) 1.04
Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res (2013) 1.03
Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol (2012) 0.98
Inflammatory mediators of hepatic steatosis. Mediators Inflamm (2010) 0.91
Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res (2012) 0.90
Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogenesis Tissue Repair (2012) 0.90
Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury. Genome Med (2013) 0.87
Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol (2010) 0.85
Liver proteomics in progressive alcoholic steatosis. Toxicol Appl Pharmacol (2012) 0.85
Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci (2010) 0.84
Biochemical determination of lipid content in hepatic steatosis by the Soxtec method. World J Gastroenterol (2010) 0.82
Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. PLoS One (2015) 0.82
Role of hemostatic factors in hepatic injury and disease: animal models de-liver. J Thromb Haemost (2016) 0.80
Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example. PLoS One (2013) 0.80
Utility of formalin-fixed, paraffin-embedded liver biopsy specimens for global proteomic analysis in nonalcoholic steatohepatitis. Proteomics Clin Appl (2011) 0.80
Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis. World J Gastroenterol (2014) 0.80
The effects of diet composition on body fat and hepatic steatosis in an animal (Peromyscus californicus) model of the metabolic syndrome. Comp Med (2011) 0.80
Identification of a metabolic biomarker panel in rats for prediction of acute and idiosyncratic hepatotoxicity. Comput Struct Biotechnol J (2014) 0.79
Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.78
ADV36 adipogenic adenovirus in human liver disease. World J Gastroenterol (2014) 0.76
Mitochondrial Molecular Pathophysiology of Nonalcoholic Fatty Liver Disease: A Proteomics Approach. Int J Mol Sci (2016) 0.75
Biomarkers in liver disease: emerging methods and potential applications. Int J Hepatol (2012) 0.75
Serum complement C3f and fibrinopeptide A are potential novel diagnostic biomarkers for non-alcoholic fatty liver disease: a study in Qingdao Twins. PLoS One (2014) 0.75
Molecular signatures of nonalcoholic fatty liver disease: the present and future. Hepatology (2010) 0.75
Topological and functional analysis of nonalcoholic steatohepatitis through protein interaction mapping. Gastroenterol Hepatol Bed Bench (2016) 0.75
Proteomic profiling of cellular steatosis with concomitant oxidative stress in vitro. Lipids Health Dis (2016) 0.75
Pediatric Non-Alcoholic Fatty Liver Disease. J Med Biochem (2014) 0.75
Tomato Juice Consumption Modifies the Urinary Peptide Profile in Sprague-Dawley Rats with Induced Hepatic Steatosis. Int J Mol Sci (2016) 0.75
Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD. J Proteome Res (2016) 0.75
Proteomic Profiling of Liver and Plasma in Chronic Ethanol Feeding Model of Hepatic Alcohol Dehydrogenase-Deficient Deer Mice. Alcohol Clin Exp Res (2017) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom (1994) 45.51
TANDEM: matching proteins with tandem mass spectra. Bioinformatics (2004) 17.41
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature (2005) 10.10
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology (1994) 5.22
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology (2008) 3.60
Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res (2006) 3.51
Alcoholic liver disease. Lancet (1995) 2.97
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Label-free protein quantification using LC-coupled ion trap or FT mass spectrometry: Reproducibility, linearity, and application with complex proteomes. J Proteome Res (2006) 2.64
Retinol-binding protein 4 in human obesity. Diabetes (2006) 2.17
Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 2.11
Comprehensive label-free method for the relative quantification of proteins from biological samples. J Proteome Res (2005) 1.81
Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics (2006) 1.69
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65
Liver fibrosis: from the bench to clinical targets. Dig Liver Dis (2004) 1.58
The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci (2009) 1.57
A simplified procedure for the reduction and alkylation of cysteine residues in proteins prior to proteolytic digestion and mass spectral analysis. Anal Biochem (2004) 1.38
Label-free mass spectrometry-based protein quantification technologies in proteomic analysis. Brief Funct Genomic Proteomic (2008) 1.32
Estimating the statistical significance of peptide identifications from shotgun proteomics experiments. J Proteome Res (2007) 1.30
A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology (2005) 1.29
A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J Proteome Res (2008) 1.27
Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int (2005) 1.27
Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology (2003) 1.25
Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology (2009) 1.21
Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol (Oxf) (2007) 1.13
Clinical aspects of fatty liver disease. Semin Liver Dis (2004) 1.11
Lipid metabolism in liver and selected tissues and in the whole body of ruminant animals. Prog Lipid Res (1979) 1.10
Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol (2006) 1.07
Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology (1999) 0.99
Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 0.98
New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol (2006) 0.97
Mass spectrometry-based quantitative proteomic profiling. Brief Funct Genomic Proteomic (2005) 0.96
Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol (2003) 0.93
Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation (2009) 0.90
The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci (2007) 0.89
Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2003) 0.88
[Out of phase magnetic resonance imaging and liver applications]. J Radiol (2005) 0.81
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology (2014) 4.04
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (2008) 2.66
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol Cell Proteomics (2009) 2.39
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest Endosc (2009) 2.30
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23
Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses. Mol Cell Proteomics (2009) 2.09
Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction. Transplantation (2014) 2.00
Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices. Dig Dis Sci (2014) 1.99
Tissue heterogeneity of the mammalian mitochondrial proteome. Am J Physiol Cell Physiol (2006) 1.97
Radiation pneumonitis in mice: a severe injury model for pneumocyte engraftment from bone marrow. Exp Hematol (2002) 1.88
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology (2009) 1.78
Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci (2005) 1.76
Human peptidoglycan recognition protein-L is an N-acetylmuramoyl-L-alanine amidase. J Biol Chem (2003) 1.74
Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int (2005) 1.71
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (2008) 1.70
Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc (2002) 1.70
Lymphangiogenesis does not occur in breast cancer. Am J Surg Pathol (2005) 1.65
Fatty pancreas: a factor in postoperative pancreatic fistula. Ann Surg (2007) 1.62
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology (2009) 1.59
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology (2010) 1.58
Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis (2007) 1.56
Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci (2011) 1.52
Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol (2004) 1.48
Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol (2010) 1.48
Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2015) 1.46
Langerhans' cell histiocytosis involving the pituitary, thyroid, lung, and liver. Endocr Pract (2002) 1.45
Nonalcoholic fatty pancreas disease. HPB (Oxford) (2007) 1.44
Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol (2004) 1.43
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
Value of diffusion-weighted MRI for assessing liver fibrosis and cirrhosis. AJR Am J Roentgenol (2009) 1.36
A multiple reaction monitoring method for absolute quantification of the human liver alcohol dehydrogenase ADH1C1 isoenzyme. Anal Biochem (2007) 1.32
Label-free mass spectrometry-based protein quantification technologies in proteomic analysis. Brief Funct Genomic Proteomic (2008) 1.32
The impact of videorecording on the quality of colonoscopy performance: a pilot study. Am J Gastroenterol (2010) 1.28
Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol (2007) 1.24
Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res (2006) 1.23
In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med (2003) 1.22
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Biochemical analysis of the damage recognition process in nucleotide excision repair. J Biol Chem (2002) 1.20
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol (2010) 1.19
Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. Diabetes (2004) 1.18
Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. J Clin Gastroenterol (2007) 1.18
Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J Am Coll Surg (2009) 1.18
Altitude ammonia-oxidizing bacteria and archaea in soils of Mount Everest. FEMS Microbiol Ecol (2009) 1.17
Proteomic analysis of blastema formation in regenerating axolotl limbs. BMC Biol (2009) 1.16
Validation of a multivariate model predicting presence and size of varices. J Clin Gastroenterol (2007) 1.15
Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol (2003) 1.14
At what scale should microarray data be analyzed? Am J Pharmacogenomics (2004) 1.14
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology (2011) 1.12
The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics (2005) 1.12
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr (2011) 1.12
Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol (2010) 1.10
Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci (2008) 1.10
Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis (2009) 1.10
Correlation of CT enteroclysis with surgical pathology in Crohn's disease. Am J Gastroenterol (2007) 1.10
Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis (2004) 1.09
Identification of serum N-acetylmuramoyl-l-alanine amidase as liver peptidoglycan recognition protein 2. Biochim Biophys Acta (2005) 1.09
Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol (2008) 1.08
NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials? Gastroenterology (2013) 1.08
Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes (2003) 1.08
Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol Cancer (2010) 1.08
Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci (2005) 1.07
Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis (2012) 1.06
Differential effects of ethanol in the nucleus accumbens shell of alcohol-preferring (P), alcohol-non-preferring (NP) and Wistar rats: a proteomics study. Pharmacol Biochem Behav (2009) 1.06
Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol (2011) 1.05
LC/MS-based quantitative proteomic analysis of paraffin-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis. PLoS One (2009) 1.05
Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology (2002) 1.05
Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain. Proc Natl Acad Sci U S A (2014) 1.05
Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep (2008) 1.03
Zebrafish peptidoglycan recognition proteins are bactericidal amidases essential for defense against bacterial infections. Immunity (2007) 1.02
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol (2011) 1.02
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology (2002) 1.02